hydroxychloroquine has been researched along with Purpura, Thrombocytopenic, Idiopathic in 11 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Purpura, Thrombocytopenic, Idiopathic: Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral prednisone alone was used in 50 of the 59 patients (mean initial dose 1 mg/kg body weight/day)." | 2.70 | Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. ( Arnal, C; Bierling, P; Godeau, B; Hachulla, E; Léone, J; Papo, T; Piette, JC; Roudot-Thoraval, F; Schaeffer, A; Taillan, B, 2002) |
| "Selection of patients with chronic immune thrombocytopenia from the French national prospective cohort of pediatric autoimmune cytopenia OBS'CEREVANCE and VIGICAIRE study, treated by splenectomy, hydroxychloroquine, azathioprine, or rituximab as a first second-line treatment." | 1.62 | Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation. ( Abou Chahla, W; Aladjidi, N; Armari-Alla, C; Barlogis, V; Bayart, S; Bertrand, Y; Cheikh, N; Ducassou, S; Fernandes, H; Guitton, C; Kherfellah, D; Laghouati, S; Leblanc, T; Leverger, G; Pasquet, M; Pellier, I; Savel, H; Thiébaut, R; Thomas, C; Vassal, G, 2021) |
| "Hydroxychloroquine was administered to children with positive antinuclear antibodies, more frequently older and girls, and reached 55% efficacy." | 1.56 | Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. ( Abouchallah, W; Aladjidi, N; Bayart, S; Bertrand, Y; Carausu, L; Cheikh, N; Droz, C; Ducassou, S; Fernandes, H; Fouyssac, F; Gourdonneau, A; Guitton, C; Jeziorski, E; Leblanc, T; Leverger, G; Michel, G; Pasquet, M; Pellier, I; Thomas, C; Viard, F, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, F | 1 |
| Tang, Q | 1 |
| Cheng, W | 1 |
| Xie, X | 1 |
| Li, F | 1 |
| Chen, J | 1 |
| Ducassou, S | 2 |
| Gourdonneau, A | 1 |
| Fernandes, H | 2 |
| Leverger, G | 3 |
| Pasquet, M | 3 |
| Fouyssac, F | 1 |
| Bayart, S | 3 |
| Bertrand, Y | 2 |
| Michel, G | 1 |
| Jeziorski, E | 1 |
| Thomas, C | 3 |
| Abouchallah, W | 1 |
| Viard, F | 1 |
| Guitton, C | 2 |
| Cheikh, N | 2 |
| Pellier, I | 3 |
| Carausu, L | 1 |
| Droz, C | 1 |
| Leblanc, T | 3 |
| Aladjidi, N | 3 |
| Mathian, A | 1 |
| Amoura, Z | 1 |
| Fanouriakis, A | 1 |
| Tziolos, N | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| Savel, H | 1 |
| Abou Chahla, W | 1 |
| Barlogis, V | 1 |
| Armari-Alla, C | 1 |
| Kherfellah, D | 1 |
| Vassal, G | 1 |
| Thiébaut, R | 1 |
| Laghouati, S | 1 |
| Blasco, LM | 1 |
| Khellaf, M | 1 |
| Chabrol, A | 1 |
| Mahevas, M | 1 |
| Roudot-Thoraval, F | 2 |
| Limal, N | 1 |
| Languille, L | 1 |
| Bierling, P | 2 |
| Michel, M | 1 |
| Godeau, B | 3 |
| Audia, S | 1 |
| Bonnotte, B | 1 |
| Roche, O | 1 |
| Rakotonjanahary, J | 1 |
| Courcoux, MF | 1 |
| Gilibert-Yvert, M | 1 |
| Neven, B | 1 |
| Quartier, P | 1 |
| Knight, AK | 1 |
| Cunningham-Rundles, C | 1 |
| Arnal, C | 1 |
| Piette, JC | 1 |
| Léone, J | 1 |
| Taillan, B | 1 |
| Hachulla, E | 1 |
| Papo, T | 1 |
| Schaeffer, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "French National Cohort of Patients With Pediatric-onset of Autoimmune Cytopenia (OBS'CEREVANCE Cohort)"[NCT05937828] | 3,500 participants (Anticipated) | Observational [Patient Registry] | 2010-09-01 | Recruiting | |||
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus[NCT02444728] | Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Because of insufficient enrollement) | ||
| Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia Among 40 Patients[NCT01549184] | 40 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia[NCT03229746] | Phase 4 | 40 participants (Actual) | Interventional | 2017-08-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxychloroquine and Purpura, Thrombocytopenic, Idiopathic
| Article | Year |
|---|---|
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
Inflammatory and autoimmune complications of common variable immune deficiency.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
2 trials available for hydroxychloroquine and Purpura, Thrombocytopenic, Idiopathic
| Article | Year |
|---|---|
Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP).
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Hydroxychloroquine; Infant; Infant, Newborn; Ma | 2017 |
Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Danazol; Drug Administration Routes; Dru | 2002 |
7 other studies available for hydroxychloroquine and Purpura, Thrombocytopenic, Idiopathic
| Article | Year |
|---|---|
Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sjögren syndrome.
Topics: Hemorrhage; Humans; Hydroxychloroquine; Purpura, Thrombocytopenic, Idiopathic; Retrospective Studies | 2023 |
Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years.
Topics: Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Combined Modality Therapy; Female; Fol | 2020 |
Response to: 'Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idio | 2021 |
Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydroxychloroqui | 2021 |
Hydroxychloroquine alone for severe immune thrombocytopenic purpura associated with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Purp | 2013 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Female; Humans; Hydroxychloroquine | 2014 |
Is there still a place for "old therapies" in the management of immune thrombocytopenia?
Topics: Benzoates; Danazol; Dapsone; Humans; Hydrazines; Hydroxychloroquine; Immunoglobulins, Intravenous; P | 2016 |